Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, Marketbeat Ratings reports.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. Jefferies Group LLC reiterated a “buy” rating and issued a $32.00 price target on shares of Zynerba Pharmaceuticals in a research note on Thursday, May 25th. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 price target on shares of Zynerba Pharmaceuticals in a research note on Tuesday, May 9th. BidaskClub upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, HC Wainwright set a $30.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $31.44.

Zynerba Pharmaceuticals (ZYNE) traded down 55.71% during trading on Monday, reaching $6.67. The company’s stock had a trading volume of 8,995,955 shares. The stock’s market cap is $88.42 million. Zynerba Pharmaceuticals has a 52-week low of $5.93 and a 52-week high of $25.95. The firm’s 50-day moving average is $17.81 and its 200-day moving average is $19.61.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings data on Tuesday, August 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by $0.04. Equities research analysts forecast that Zynerba Pharmaceuticals will post ($2.46) EPS for the current year.

WARNING: “Zynerba Pharmaceuticals, Inc. (ZYNE) Lowered to Hold at Maxim Group” was posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/07/zynerba-pharmaceuticals-inc-nasdaqzyne-receives-hold-rating-from-maxim-group.html.

In other news, CFO James E. Fickenscher acquired 5,200 shares of the stock in a transaction on Friday, May 12th. The stock was acquired at an average cost of $19.82 per share, for a total transaction of $103,064.00. Following the completion of the transaction, the chief financial officer now directly owns 12,200 shares in the company, valued at $241,804. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Armando Anido acquired 5,000 shares of the stock in a transaction on Monday, May 15th. The shares were purchased at an average price of $19.70 per share, with a total value of $98,500.00. Following the completion of the transaction, the chairman now owns 336,012 shares of the company’s stock, valued at $6,619,436.40. The disclosure for this purchase can be found here. 10.02% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ZYNE. Marshall Wace North America L.P. purchased a new position in shares of Zynerba Pharmaceuticals during the first quarter valued at approximately $9,362,000. Vanguard Group Inc. increased its position in shares of Zynerba Pharmaceuticals by 53.9% in the first quarter. Vanguard Group Inc. now owns 425,811 shares of the company’s stock valued at $8,559,000 after buying an additional 149,094 shares in the last quarter. Pennsylvania Trust Co purchased a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at approximately $2,366,000. Sphera Funds Management LTD. purchased a new position in shares of Zynerba Pharmaceuticals during the first quarter valued at approximately $2,010,000. Finally, Granite Point Capital Management L.P. purchased a new position in shares of Zynerba Pharmaceuticals during the first quarter valued at approximately $1,990,000. Institutional investors and hedge funds own 31.08% of the company’s stock.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.